Pharmaceutical compounds
US7696204B2 · kind B2 · utility
24Cited by
1References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 11, 2006 |
| Grant date | Apr 13, 2010 |
| Priority date | — |
| Expiry date | Oct 11, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pyrimidines of formula (I):wherein R1 to R4, X and Y are defined in the specification are inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.